Twist Bioscience Corporation— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$638M
↑+4.8% +$30Mvs FY2024
Total Liabilities
$182M
↑+19.2% +$29Mvs FY2024
Equity
$456M
↑+0.0% +$154Kvs FY2024
Cash
$149M
↓-32.9% -$73Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $638M | $609M |
| Current Assets | $304M | $345M |
| Cash | $149M | $221M |
| ST Investments | $49M | $49M |
| Receivables | $50M | $39M |
| Inventory | $33M | $24M |
| Other Current | $23M | $12M |
| Non-Current Assets | $334M | $263M |
| PPE | $105M | $101M |
| Goodwill | $82M | $86M |
| Intangibles | $13M | $14M |
| Investments | $0 | $0 |
| Other Non-Current | $134M | $63M |
| Total Liab+Eq | $638M | $609M |
| Current Liab. | $80M | $70M |
| Accounts Payable | $12M | $8M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $9M | $1M |
| Other CL | $59M | $61M |
| Non-Current Liab. | $102M | $83M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $102M | $83M |
| Equity | $456M | $456M |
| Retained Earnings | $1.35B | $1.27B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · TWST · Comparing FY2025 vs FY2024